S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
Sell every Stock except ONE (Ad)
Turkey's Erdogan declares victory in presidential runoff, extends rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
Sell every Stock except ONE (Ad)
Turkey's Erdogan declares victory in presidential runoff, extends rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
Sell every Stock except ONE (Ad)
Turkey's Erdogan declares victory in presidential runoff, extends rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Biden and GOP rush to finalize debt ceiling deal, shore up support to prevent default
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
'Succession' fans brace for series finale of Emmy-winning hit drama
Sell every Stock except ONE (Ad)
Turkey's Erdogan declares victory in presidential runoff, extends rule into 3rd decade
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
NASDAQ:RAPT

RAPT Therapeutics (RAPT) Stock Forecast, Price & News

$20.35
+0.30 (+1.50%)
(As of 05/26/2023 ET)
Compare
Today's Range
$19.98
$20.48
50-Day Range
$16.06
$21.34
52-Week Range
$12.85
$32.45
Volume
168,963 shs
Average Volume
298,918 shs
Market Capitalization
$699.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.22

RAPT Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
102.6% Upside
$41.22 Price Target
Short Interest
Bearish
8.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
1.40mentions of RAPT Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$242,500 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.18) to ($3.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

488th out of 1,012 stocks

Pharmaceutical Preparations Industry

230th out of 495 stocks


RAPT stock logo

About RAPT Therapeutics (NASDAQ:RAPT) Stock

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPT Stock News Headlines

Why 2023 Could Kick Off a "Cash Frenzy" in Stocks
But the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.
Analyst Expectations for RAPT Therapeutics's Future
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks
But the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.
Recap: RAPT Therapeutics Q1 Earnings
RAPT Therapeutics (NASDAQ:RAPT) Shares Gap Up to $16.77
RAPT Therapeutics (NASDAQ:RAPT) Shares Down 5.3%
RAPT Therapeutics: Potential Strong Upside Ahead
See More Headlines
Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPT Company Calendar

Last Earnings
3/14/2023
Today
5/28/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RAPT
Fax
N/A
Employees
81
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$41.22
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+102.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-83,840,000.00
Pretax Margin
-10,456.09%

Debt

Sales & Book Value

Annual Sales
$1.53 million
Book Value
$6.42 per share

Miscellaneous

Free Float
32,456,000
Market Cap
$699.02 million
Optionable
Not Optionable
Beta
0.37

Social Links


Key Executives

  • Brian Russell Wong
    President, Chief Executive Officer & Director
  • Rodney K. B. Young
    Chief Financial Officer & Secretary
  • William HoWilliam Ho
    Chief Medical Officer
  • Dirk G. BrockstedtDirk G. Brockstedt
    Chief Scientific Officer
  • Jim Farmer
    Vice President-Clinical Operations













RAPT Stock - Frequently Asked Questions

Should I buy or sell RAPT Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RAPT shares.
View RAPT analyst ratings
or view top-rated stocks.

What is RAPT Therapeutics' stock price forecast for 2023?

8 brokers have issued twelve-month price objectives for RAPT Therapeutics' shares. Their RAPT share price forecasts range from $23.00 to $48.00. On average, they expect the company's stock price to reach $41.22 in the next twelve months. This suggests a possible upside of 102.6% from the stock's current price.
View analysts price targets for RAPT
or view top-rated stocks among Wall Street analysts.

How have RAPT shares performed in 2023?

RAPT Therapeutics' stock was trading at $19.80 at the start of the year. Since then, RAPT stock has increased by 2.8% and is now trading at $20.35.
View the best growth stocks for 2023 here
.

When is RAPT Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RAPT earnings forecast
.

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) released its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.03.

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

When did RAPT Therapeutics IPO?

(RAPT) raised $39 million in an IPO on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank acted as the underwriters for the IPO.

What is RAPT Therapeutics' stock symbol?

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (13.00%), Price T Rowe Associates Inc. MD (9.67%), Perceptive Advisors LLC (6.67%), BlackRock Inc. (6.33%), State Street Corp (4.77%) and Great Point Partners LLC (3.95%). Insiders that own company stock include Brian Russell Wong, Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends
.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RAPT Therapeutics' stock price today?

One share of RAPT stock can currently be purchased for approximately $20.35.

How much money does RAPT Therapeutics make?

RAPT Therapeutics (NASDAQ:RAPT) has a market capitalization of $699.02 million and generates $1.53 million in revenue each year. The company earns $-83,840,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How can I contact RAPT Therapeutics?

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.rapt.com. The company can be reached via phone at (650) 489-9000 or via email at investors@rapt.com.

This page (NASDAQ:RAPT) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -